Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables

Original Article by Jacob Webster | Business Day | 4 March 2026

Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.

Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

NHLS Scrambles as Pathology Services Funding Runs Dry

The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt

Read more...

Momentum Group Posts Record Earnings

Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.

Read more...

Sanlam Writes Down AfroCentric to Nil but Won’t Sell

Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.

Read more...